Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2005
03/10/2005US20050054595 Genetic engineering; gene expression of target agent
03/10/2005US20050054592 Alzheimer's disease; Parkinson's disease; isolated nucleic acids
03/10/2005US20050054582 Para-amino benzoic acids as integrin antagonists
03/10/2005US20050054580 Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
03/10/2005US20050054577 Irritable bowel disorders; controlling permeability of intestine tissue ; anticholinergic agent
03/10/2005US20050053659 Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
03/10/2005US20050053647 Pharmaceutical product comprising the active substance diamorphine, and its use in a process for treating opiate addiction
03/10/2005US20050053601 Protein with amino acid sequences for central nervous systems in mammals
03/10/2005US20050053583 Method of inhibiting prion protein
03/10/2005US20050053577 Linking low molecular weight drugs containing a carboxylic acid group and an amine, thiol, alcohol or phenol, which is released when hydrolysis occurs; for treatment of cancer
03/10/2005CA2537535A1 Novel medical use of selective cb1-receptor antagonists
03/10/2005CA2537364A1 Imidazo[1,5-a]pyridine or imidazo[1,5-a]piperidine derivatives and their use for the preparation of medicament against 5-ht2a receptor-related disorders
03/10/2005CA2537349A1 The claimed invention relates to novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-ht2a receptor-related disorders
03/10/2005CA2537090A1 Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
03/10/2005CA2537088A1 Using selective antagonists of persistent sodium current to treat neurological disorders and pain
03/10/2005CA2537060A1 Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
03/10/2005CA2536910A1 Oral neurotherapeutic cefazolin compositions
03/10/2005CA2536461A1 Aryl piperidine amides
03/10/2005CA2536161A1 Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
03/10/2005CA2533690A1 Use of a polyamine-poor composition for the production of a medical human food
03/10/2005CA2532349A1 Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
03/10/2005CA2530014A1 Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
03/10/2005CA2510677A1 Amino acid derived prodrugs of propofol, compositions and uses thereof
03/09/2005EP1512739A1 Chrondrocyte therapeutic delivery system
03/09/2005EP1512688A1 Use of K-252a derivatives for the treatment of Parkinson's disease
03/09/2005EP1512683A1 Novel opiate compounds, methods of making and methods of use
03/09/2005EP1512679A1 Novel adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them
03/09/2005EP1512414A1 Hapten-carrier conjugates for treating and preventing nicotine addiction
03/09/2005EP1512411A1 Treatment of neuromuscular disorders and conditions with different botulinum serotype
03/09/2005EP1512403A1 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
03/09/2005EP1512400A1 Treatment of neurodegenerative diseases
03/09/2005EP1512013A2 Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases
03/09/2005EP1512008A1 Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action
03/09/2005EP1511853A2 Regulation of novel human asparagine-hydroxylases
03/09/2005EP1511770A2 Immunoadhesin comprising a glycoprotein vi domain
03/09/2005EP1511759A1 Modulators and inhibitors of fibroblast growth factor receptor 5-polypeptides and gene expression thereof.
03/09/2005EP1511748A1 8-fluorimidazo(1,2-a)pyridine derivatives as ligands for gaba receptors
03/09/2005EP1511747A1 Imidazo-pyridine derivatives as ligands for gaba receptors
03/09/2005EP1511744A2 Bis-benzimidazoles and related compounds as potassium channel modulators
03/09/2005EP1511743A1 Pyrazole-derivatives as p38 kinase inhibitors
03/09/2005EP1511741A1 Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
03/09/2005EP1511740A1 Phenyl-thiophene type vitamin d receptor modulators
03/09/2005EP1511737A1 Aryloximes
03/09/2005EP1511736A1 Therapeutic molecules and methods-1
03/09/2005EP1511735A1 Imidazole compounds and their use as ligands of the alpha-" adrenoreceptors
03/09/2005EP1511730A2 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
03/09/2005EP1511728A2 Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics
03/09/2005EP1511727A2 Aromatic sulfones and their medical use
03/09/2005EP1511726A1 Method for preparing 1,3,5-triaminobenzene and hydrolyzing it into high-purity phloroglucinol
03/09/2005EP1511723A1 Sulfone liver x-receptor modulators
03/09/2005EP1511722A1 Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof
03/09/2005EP1511719A1 Amide derivatives as inhibitors of the enzymatic activity of renin
03/09/2005EP1511718A1 N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors
03/09/2005EP1511716A2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
03/09/2005EP1511710A1 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer s disease, type 2 diabetes, and parkinson s disease
03/09/2005EP1511512A1 Novel uses of parapoxvirus preparations
03/09/2005EP1511507A1 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
03/09/2005EP1511502A2 Probiotic therapies using lactobacillus reuteri
03/09/2005EP1511499A2 Immunomodulatory compounds and methods of use thereof
03/09/2005EP1511496A1 Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
03/09/2005EP1511494A1 Androgen pharmaceutical composition and method for treating depression
03/09/2005EP1511490A2 Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
03/09/2005EP1511489A1 New pharmaceutical compositions containing flibanserin polymorph a
03/09/2005EP1511487A1 Novel formulation for the parenteral application of crobenetine
03/09/2005EP1511486A1 Use of dopamine partial agonists for the treatment of the restless legs syndrome and corresponding pharmaceutical preparation
03/09/2005EP1511485A1 Novel uses of dl-thp
03/09/2005EP1511483A2 Methods of treatment with lxr modulators
03/09/2005EP1511480A2 Inhibitors of glycoprotein vi
03/09/2005EP1511479A1 Treatment of neuropathic pain
03/09/2005EP1511474A1 A method of treatment
03/09/2005EP1511473A2 Bis-aromatic alkanols
03/09/2005EP1511468A1 Nanoparticulate sterol formulations and sterol combinations
03/09/2005EP1511467A1 Nanoparticulate polycosanol formulations and novel polycosanol combinations
03/09/2005EP1451188B1 4-(oxadiazol-3-yl)-1,4-diazabicyclo 3.2.2]-nonane derivatives, preparation and therapeutic use thereof
03/09/2005EP1432407B1 Lisinopril compositions having large-particle dcpd
03/09/2005EP1370549A4 Methods for the preparation of mirtazapine intermediates
03/09/2005EP1345892B1 Acylaminoalkyl-substituted benzenesulfonamide derivatives
03/09/2005EP1289512B1 Agents and methods for increasing brain chaperonin levels
03/09/2005EP1272499B1 Pharmaceutical compositions containing oligosaccharides and preparation thereof
03/09/2005EP1162959B1 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
03/09/2005EP1140112B1 Etherlysophospholipids for the treatment of chronic inflammatory diseases
03/09/2005EP1126849B1 Heterocyclic potassium channel inhibitors
03/09/2005EP1108026B1 Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same
03/09/2005EP0998276B1 Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders
03/09/2005EP0991408B1 Novel process for manufacturing paroxetine solid dispersions
03/09/2005EP0944645B1 INHIBITORS OF INTERLEUKIN-1beta CONVERTING ENZYME
03/09/2005EP0848592B2 Antistress agents for aquatic animals
03/09/2005EP0839149B9 Galanthamine derivatives, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing such derivatives
03/09/2005EP0817627B1 Protein kinase c inhibitors
03/09/2005EP0801679B1 Monoclonal antibodies which promote central nervous system remyelination
03/09/2005CN1592747A Diazabicyclo alkane derivatives with NK1 antagonistic activity
03/09/2005CN1592745A Therapeutic chromone compounds
03/09/2005CN1592744A Thiazole derivatives having CB1-antagonistic, agonistic or partial agonistic activity
03/09/2005CN1592743A Inhibitors of glycogen synthase kinase 3
03/09/2005CN1592742A Neurotensin active 2, 3-diaryl-pyrazolidine derivatives
03/09/2005CN1592739A Novel piperidine based MCH antagonists for treatment of obesity and CNS disorders
03/09/2005CN1592645A Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory anti-body combination
03/09/2005CN1592643A Methods and apparatuses for assuring quality and safety of drug administration and medical products and kits
03/09/2005CN1592637A Medicinal compositions
03/09/2005CN1592623A Acetylene derivatives having human matabotropic glutamate receptor antagonistic activity
1 ... 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 ... 1833